CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Shares	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Valeant Pharmaceuticals International, Inc. Shareholders' Equity	Noncontrolling Interest
Balance (in shares) at Dec. 31, 2012		303,900,000.0
Beginning Balance at Dec. 31, 2012	$ 3,717.4	$ 5,940.7	$ 267.1	$ (2,371.0)	$ (119.4)	$ 3,717.4	$ 0.0
Increase (Decrease) in Shareholders' Equity
Issuance of common stock (in shares)		27,600,000.0
Issuance of common stock	2,306.9	$ 2,306.9				2,306.9
Common shares issued under share-based compensation plans (in shares)		2,200,000.0
Common shares issued under share-based compensation plans	6.4	$ 67.8	(61.4)			6.4
Repurchase of common shares (in shares)		(700,000.0)
Repurchase of common shares	(55.6)	$ (14.2)		(41.4)		(55.6)
Share-based compensation	45.5		45.5			45.5
Employee withholding taxes related to share-based awards	(46.6)		(46.6)			(46.6)
Tax benefits from share-based compensation	24.2		24.2			24.2
Noncontrolling interest from business combinations	113.9						113.9
Noncontrolling interest distributions	(2.1)						(2.1)
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	(866.1)
Comprehensive income:
Net (loss) income	(863.6)			(866.1)		(866.1)	2.5
Other comprehensive income (loss)	(13.1)				(13.4)	(13.4)	0.3
Comprehensive (loss) income	(876.7)					(879.5)	2.8
Balance (in shares) at Dec. 31, 2013		333,000,000
Ending Balance at Dec. 31, 2013	5,233.3	$ 8,301.2	228.8	(3,278.5)	(132.8)	5,118.7	114.6
Increase (Decrease) in Shareholders' Equity
Total before comprehensive income (loss) (in shares)		333,000,000
Total before comprehensive income (loss)	6,110.0	$ 8,301.2	228.8	(2,412.4)	(119.4)	5,998.2	111.8
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	$ 368.2
Balance (in shares) at Sep. 30, 2014	334,004,879
Balance (in shares) at Dec. 31, 2013		333,000,000
Beginning Balance at Dec. 31, 2013	$ 5,233.3	$ 8,301.2	228.8	(3,278.5)	(132.8)	5,118.7	114.6
Increase (Decrease) in Shareholders' Equity
Common shares issued under share-based compensation plans (in shares)		1,400,000.0
Common shares issued under share-based compensation plans	16.1	$ 48.0	(31.9)			16.1
Settlement of stock options	(3.1)		(3.1)			(3.1)
Share-based compensation	78.2		78.2			78.2
Employee withholding taxes related to share-based awards	(44.1)		(44.1)			(44.1)
Tax benefits from share-based compensation	17.1		17.1			17.1
Noncontrolling interest from business combinations	15.0						15.0
Acquisition of noncontrolling interest	(3.3)		(1.1)			(1.1)	(2.2)
Noncontrolling interest distributions	(2.2)						(2.2)
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	880.7
Comprehensive income:
Net (loss) income	879.4			880.7		880.7	(1.3)
Other comprehensive income (loss)	(784.7)				(783.1)	(783.1)	(1.6)
Comprehensive (loss) income	$ 94.7					97.6	(2.9)
Balance (in shares) at Dec. 31, 2014	334,402,964	334,400,000.0
Ending Balance at Dec. 31, 2014	$ 5,401.7	$ 8,349.2	243.9	(2,397.8)	(915.9)	5,279.4	122.3
Balance (in shares) at Sep. 30, 2014	334,004,879
Increase (Decrease) in Shareholders' Equity
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	$ 512.5
Balance (in shares) at Dec. 31, 2014	334,402,964	334,400,000.0
Ending Balance at Dec. 31, 2014	$ 5,401.7	$ 8,349.2	243.9	(2,397.8)	(915.9)	5,279.4	122.3
Increase (Decrease) in Shareholders' Equity
Total before comprehensive income (loss) (in shares)		334,400,000.0
Total before comprehensive income (loss)	5,307.0	$ 8,349.2	243.9	(3,278.5)	(132.8)	5,181.8	125.2
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	$ 97.7
Balance (in shares) at Mar. 31, 2015	342,266,409
Balance (in shares) at Dec. 31, 2014	334,402,964	334,400,000.0
Beginning Balance at Dec. 31, 2014	$ 5,401.7	$ 8,349.2	243.9	(2,397.8)	(915.9)	5,279.4	122.3
Increase (Decrease) in Shareholders' Equity
Issuance of common stock (in shares)		7,500,000.0
Issuance of common stock	1,482.3	$ 1,482.3				1,482.3
Common shares issued under share-based compensation plans (in shares)		1,400,000.0
Common shares issued under share-based compensation plans	30.2	$ 78.1	(47.9)			30.2
Repurchase of common shares (in shares)		(400,000.0)
Repurchase of common shares	(72.4)	$ (12.2)		(60.2)		(72.4)
Share-based compensation	140.1		140.1			140.1
Employee withholding taxes related to share-based awards	(88.0)		(88.0)			(88.0)
Tax benefits from share-based compensation	56.8		56.8			56.8
Noncontrolling interest from business combinations	4.9						4.9
Noncontrolling interest distributions	(8.5)						(8.5)
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	(291.7)
Comprehensive income:
Net (loss) income	(287.8)			(291.7)		(291.7)	3.9
Other comprehensive income (loss)	(629.5)				(625.7)	(625.7)	(3.8)
Comprehensive (loss) income	$ (917.3)					(917.4)	0.1
Balance (in shares) at Dec. 31, 2015	342,926,531	342,900,000.0
Ending Balance at Dec. 31, 2015	$ 6,029.8	$ 9,897.4	304.9	(2,749.7)	(1,541.6)	5,911.0	118.8
Increase (Decrease) in Shareholders' Equity
Total before comprehensive income (loss) (in shares)		342,900,000.0
Total before comprehensive income (loss)	$ 6,947.1	$ 9,897.4	$ 304.9	$ (2,458.0)	$ (915.9)	$ 6,828.4	$ 118.7